Literature DB >> 3127851

Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine.

S J Dencker1, R Johansson, U Malm.   

Abstract

Six chronic schizophrenics--earlier refractory to recommended doses of neuroleptic drugs but eventually responding to 250 mg fluphenazine heptanoate weekly--participated in a pharmacokinetic study. Five out of the six patients showed rather constant steady state plasma fluphenazine values on a 250 mg depot weekly. After depot drug withdrawal, the single oral dose pharmacokinetics on 400 mg fluphenazine showed the same variations in Cmax, tmax, t 1/2 and AUC as are observed when recommended doses of fluphenazine are used. We thus could not demonstrate any dose-dependent pharmacokinetics on high oral fluphenazine doses. In half the patients, a biphasic decay in the plasma concentration curve indicated at least two compartments. The patients were then studied for up to 2 years on 200-500 mg fluphenazine as a single daily dose. The fluphenazine plasma levels were rather constant in the individual patients during this period. The plasma prolactin values were related to the fluphenazine values even in the high value area, thus showing a persistent pharmacodynamic variation capacity. The clinical part of the study did not show any relevant findings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127851     DOI: 10.1007/bf00176852

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Determination of fluphenazine in plasma by ion-pair partition chromatography.

Authors:  R Johansson; K O Borg; M Gabrielsson
Journal:  Acta Pharm Suec       Date:  1976

3.  A comprehensive psychopathological rating scale.

Authors:  M Asberg; S A Montgomery; C Perris; D Schalling; G Sedvall
Journal:  Acta Psychiatr Scand Suppl       Date:  1978

4.  The inter-rater reliability of scales for rating symptoms and side-effects in schizophrenic patients during a drug trial.

Authors:  K Andersen; U Malm; C Perris; W Rapp; G Román
Journal:  Acta Psychiatr Scand Suppl       Date:  1974

5.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

6.  Kinetics of oral fluphenazine disposition in humans by GC-MS.

Authors:  K K Midha; G McKay; R Edom; E D Korchinski; E M Hawes; K Hall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  High doses of fluphenazine enanthate in schizophrenia. A controlled study.

Authors:  S J Dencker; R Johansson; L Lundin; U Malm
Journal:  Acta Psychiatr Scand       Date:  1978-05       Impact factor: 6.392

8.  Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.

Authors:  S H Curry; R Whelpton; P J de Schepper; S Vranckx; A A Schiff
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

9.  Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.

Authors:  D Wiles; M Franklin; S J Dencker; R Johansson; L Lundin; U Malm
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

  9 in total
  1 in total

Review 1.  Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.

Authors:  Christoph U Correll; Edward Kim; Jennifer Kern Sliwa; Wayne Hamm; Srihari Gopal; Maju Mathews; Raja Venkatasubramanian; Stephen R Saklad
Journal:  CNS Drugs       Date:  2021-01-28       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.